Our efforts to develop innovative diagnostic technology still continue today.
SLS Bio Co., Ltd. established in 2007 has secured professional technical workforce and has actively invested in R&D. As a result, it was listed in KONEX in June of 2016. We are now in the process for KOSDAQ listing.
Through vigorous R&D investment, SLS Bio has already commercialized Fragile X and STR Kit, while preparing to commercialize products such as Allergy Rapid Diagnostic Kit and Bovine Pregnancy Rapid Diagnostic Kit in 2019. We are also planning to conduct a clinical evaluation of NTMD(Nano Technology Multiplex Diagnostic) in 2019 before its commercialization.
Also, we are planning to invest in veterinary regenerative medicine using stem cells and has invested in a related company for new drug R&D. In addition, we have accomplished continued growth in business of Quality Control for pharmaceutical products and of New Drug Efficacy Evaluation through customer satisfaction and high quality service.
SLS Bio will continue to contribute to improving Human Health Care through vigorous R&D, while striving to position our company as an ethical and trustworthy service provider in Quality Control and New Drug Efficacy Evaluation business. We look forward to your kind support and co-operation.